0 253

Cited 6 times in

The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)

DC Field Value Language
dc.contributor.author김진석-
dc.date.accessioned2022-09-06T06:40:32Z-
dc.date.available2022-09-06T06:40:32Z-
dc.date.issued2020-02-
dc.identifier.issn0939-5555-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/190257-
dc.description.abstractAlthough lenalidomide plus dexamethasone (RD) is a therapeutic option for relapsed/refractory multiple myeloma (RRMM), limited real-world clinical data exist. The purpose of this study was to estimate efficacy and safety of RD in RRMM patients of the clinical practice. Data from patients at 25 university hospitals in South Korea between October 2009 and December 2016 were collected retrospectively. We report the effectiveness and safety of RD in 546 RRMM patients in routine clinical practice in South Korea. Patients (median age, 65 years) typically received median 7 cycles of RD, and 184 (33.7%) patients were treated with 10 or more cycles of RD. Patients with renal impairment (CLCr < 40 mL/min; 10.4%), comorbid conditions (>= 2; 12.0%), and poor performance status (>= 2; 25.1%) were included. The overall response rate was 64.2%: complete response (13.1%), very good partial response (VGPR 19.9%). With median follow-up duration of 18.6 months, median PFS and OS were 11.2 months and 25.2 months, respectively. In multivariate analysis, less than 2 comorbid conditions, normal LDH, failed one chemotherapy prior to RD, and >= 10 cycles of RD therapy had significantly prolonged PFS (P = 0.007, P = 0.011, P = 0.007, and P < 0.001, respectively). Adverse events were acceptable. RD is effective and safe in real-life clinical practice, including patients with comorbidities. RD is an effective and safe treatment in a real clinical setting which includes patients with comorbidities. Early and continual use of RD treatment may improve RRMM survival outcomes.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer International-
dc.relation.isPartOfANNALS OF HEMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / administration & dosage*-
dc.subject.MESHDexamethasone / administration & dosage-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLenalidomide / administration & dosage-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultiple Myeloma / drug therapy*-
dc.subject.MESHMultiple Myeloma / mortality*-
dc.subject.MESHRecurrence-
dc.subject.MESHRepublic of Korea / epidemiology-
dc.subject.MESHSurvival Rate-
dc.titleThe effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJae-Cheol Jo-
dc.contributor.googleauthorHo Sup Lee-
dc.contributor.googleauthorKihyun Kim-
dc.contributor.googleauthorJe-Jung Lee-
dc.contributor.googleauthorSung-Soo Yoon-
dc.contributor.googleauthorSoo-Mee Bang-
dc.contributor.googleauthorJin Seok Kim-
dc.contributor.googleauthorHyeon-Seok Eom-
dc.contributor.googleauthorDok Hyun Yoon-
dc.contributor.googleauthorYoojin Lee-
dc.contributor.googleauthorHo-Jin Shin-
dc.contributor.googleauthorYong Park-
dc.contributor.googleauthorWon Sik Lee-
dc.contributor.googleauthorYoung Rok Do-
dc.contributor.googleauthorYeung-Chul Mun-
dc.contributor.googleauthorMark Hong Lee-
dc.contributor.googleauthorHyo Jung Kim-
dc.contributor.googleauthorSung-Hyun Kim-
dc.contributor.googleauthorMin Kyoung Kim-
dc.contributor.googleauthorSung-Nam Lim-
dc.contributor.googleauthorSu-Hee Cho-
dc.contributor.googleauthorSeong Kyu Park-
dc.contributor.googleauthorJun Ho Yi-
dc.contributor.googleauthorJae Hoon Lee-
dc.contributor.googleauthorJinmi Kim-
dc.contributor.googleauthorChang-Ki Min-
dc.identifier.doi10.1007/s00277-019-03904-7-
dc.contributor.localIdA01017-
dc.relation.journalcodeJ00161-
dc.identifier.eissn1432-0584-
dc.identifier.pmid31872360-
dc.identifier.urlhttps://link.springer.com/article/10.1007/s00277-019-03904-7-
dc.subject.keywordMultiple myeloma-
dc.subject.keywordLenalidomide plus dexamethasone-
dc.subject.keywordEffectiveness-
dc.subject.keywordSurvival-
dc.subject.keywordReal-world evidence-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.affiliatedAuthor김진석-
dc.citation.volume99-
dc.citation.number2-
dc.citation.startPage309-
dc.citation.endPage319-
dc.identifier.bibliographicCitationANNALS OF HEMATOLOGY, Vol.99(2) : 309-319, 2020-02-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.